title: [Daily low-dose tadalafil for erectile dysfunction induced by pelvic fracture urethral disruption].
abstract: OBJECTIVE
  To evaluate the effect of daily low-dose tadalafil on erectile dysfunction (ED) induced by pelvic fracture urethral disruption (PFUD).
  
  
  METHODS
  This study included 46 cases of PFUD-induced ED treated from Jan 2008 to Dec 2011. The patients were aged 33.9 +/- 7.2 years (range 25 -51 yr), and the interval between injury and treatment was 19.6 +/- 12.7 months (range 3 - 72 mo), all with normal erectile function before PFUD. Based on the nocturnal penile tumescence and rigidity (NPTR) recorded by erectometry without medication of phosphodiesterase type 5 inhibitor (PDE-5I), the patients were divided into an abnormal nocturnal erection group and a non-nocturnal erection group, and treated with tadalafil 10 mg once daily for 3 months. The therapeutic effect was evaluated by IIEF-5 scores and the rate of yes responses to questions 2 and 3 of the Sexual Encounter Profile (SEP).
  
  
  RESULTS
  Totally 38 (82.6%) of the patients accomplished the treatment and follow-up, 26 (68.4%) in the abnormal nocturnal erection group and 12 (31.6%) in the non-nocturnal erection group. After 3 months of daily tadalafil treatment at 10 mg, the IIEF-5 scores were significantly improved in the abnormal nocturnal erection group than in the non-nocturnal erection group (P < 0.05), and the rate of yes responses to SEP2 and SEP3 was remarkably higher in the former than in the latter (76.9% vs 41.7% and 65.4% vs 25.0%, P < 0.05).
  
  
  CONCLUSIONS
  Daily low-dose tadalafil can effectively improve the erectile function of PFUD-induced ED patients, particularly in those with nocturnal erection.
authors.affiliation: Center of Andrology, The First Hospital of Peking University, Beijing 100009, China. pengjing1979@sina.com
authors.forename: Jing
authors.initials: J
authors.lastname: Peng
authors.forename: Yi-Ming
authors.initials: YM
authors.lastname: Yuan
authors.forename: Zhi-Chao
authors.initials: ZC
authors.lastname: Zhang
authors.forename: Quan
authors.initials: Q
authors.lastname: Hong
authors.forename: Wan-Shou
authors.initials: WS
authors.lastname: Cui
authors.forename: Bing
authors.initials: B
authors.lastname: Gao
authors.forename: Wei-Dong
authors.initials: WD
authors.lastname: Song
authors.forename: Zhong-Cheng
authors.initials: ZC
authors.lastname: Xin
mesh_terms: D000328:Adult; D002243:Carbolines / Q000008:administration & dosage* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D007172:Erectile Dysfunction / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D050723:Fractures, Bone / Q000150:complications; D006801:Humans; D008297:Male; D008875:Middle Aged; D010388:Pelvis / Q000293:injuries; D010410:Penile Erection; D000068581:Tadalafil; D016896:Treatment Outcome; D014521:Urethra / Q000293:injuries
chemical_list: D002243:Carbolines; D000068581:Tadalafil